NASDAQ:GTBP GT Biopharma (GTBP) Stock Price, News & Analysis $7.49 -0.32 (-4.10%) Closing price 04:00 PM EasternExtended Trading$7.49 0.00 (0.00%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About GT Biopharma Stock (NASDAQ:GTBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GT Biopharma alerts:Sign Up Key Stats Today's Range$6.33▼$7.8050-Day Range$5.24▼$11.6352-Week Range$4.91▼$34.25Volume110,549 shsAverage Volume105,322 shsMarket Capitalization$13.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview GT Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events. The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS). Beyond GTB-3550, GT Biopharma is advancing a pipeline of preclinical TriKE constructs aimed at both hematologic and solid tumors, as well as exploring applications in infectious diseases. The modular nature of the TriKE platform enables rapid development of new molecules targeting diverse antigens, supporting strategic combination therapies and expansion into multiple oncology indications. Founded in 2015 with technology originally licensed from the National Institutes of Health, GT Biopharma is headquartered in Tempe, Arizona, and conducts research and development operations in the United States. The company collaborates with leading academic institutions and global clinical sites to advance its pipeline. Under the leadership of President and CEO Scott K. Koenig, GT Biopharma continues to pursue its mission of delivering next-generation cell-engaging therapies to improve outcomes for patients with cancer and beyond.AI Generated. May Contain Errors. Read More GT Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreGTBP MarketRank™: GT Biopharma scored higher than 14% of companies evaluated by MarketBeat, and ranked 857th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGT Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGT Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about GT Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GT Biopharma are expected to grow in the coming year, from ($10.75) to ($8.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GT Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GT Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGT Biopharma has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about GT Biopharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted215.49% of the float of GT Biopharma has been sold short.Short Interest Ratio / Days to CoverGT Biopharma has a short interest ratio ("days to cover") of 9.99.Change versus previous monthShort interest in GT Biopharma has recently decreased by 5.44%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGT Biopharma does not currently pay a dividend.Dividend GrowthGT Biopharma does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.71 News SentimentGT Biopharma has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for GT Biopharma this week, compared to 2 articles on an average week.Search Interest8 people have searched for GTBP on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows8 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GT Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders1.18% of the stock of GT Biopharma is held by insiders.Percentage Held by Institutions8.15% of the stock of GT Biopharma is held by institutions.Read more about GT Biopharma's insider trading history. Receive GTBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GTBP Stock News HeadlinesGT Biopharma consensus price target raised 2,400% to $76.50September 15 at 6:15 PM | msn.comGT Biopharma's GTB-5550 Secures FDA IND Clearance For Multiple Myeloma; Stock DownSeptember 15 at 1:13 PM | rttnews.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.September 17 at 1:00 AM | Reagan Gold Group (Ad)GT Biopharma Announces FDA Clearance of IND for GTB-5550 in Multiple Myeloma and Updates on Phase 1 TrialsSeptember 15 at 9:31 AM | quiverquant.comQGT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple MyelomaSeptember 15 at 9:15 AM | globenewswire.comGT Biopharma (NASDAQ:GTBP) Lowered to "Strong Sell" Rating by Wall Street ZenSeptember 12, 2026 | americanbankingnews.comGT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy TranscriptSeptember 11, 2026 | seekingalpha.comGT Biopharma Pops Ahead of PresentationSeptember 11, 2026 | baystreet.caSee More Headlines GTBP Stock Analysis - Frequently Asked Questions How have GTBP shares performed this year? GT Biopharma's stock was trading at $19.63 at the beginning of the year. Since then, GTBP stock has decreased by 61.8% and is now trading at $7.49. How were GT Biopharma's earnings last quarter? GT Biopharma, Inc. (NASDAQ:GTBP) issued its quarterly earnings data on Friday, August, 14th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.04. When did GT Biopharma's stock split? GT Biopharma shares reverse split before market open on Monday, February 5th 2024.The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GT Biopharma's major shareholders? Top institutional shareholders of GT Biopharma include Everhart Financial Group Inc. (0.23%), 49 Wealth Management LLC (0.14%) and 49 Wealth Management LLC (0.14%). View institutional ownership trends. How do I buy shares of GT Biopharma? Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GT Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC). Company Calendar Last Earnings8/14/2026Today9/17/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 3 days ago, GTBP's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GTBP Previous SymbolOTCMKTS:OXISD CIK109657 Webwww.gtbiopharma.com Phone(415) 919-4040FaxN/AEmployees8Year Founded1965Profitability EPS (Trailing Twelve Months)($147.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-213.16% Return on Assets-150.61% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.36 per share Price / Cash Flow20.88 Book Value$5.66 per share Price / Book1.32Miscellaneous Outstanding Shares1,800,000Free Float1,783,000Market Cap$13.48 million OptionableNo Data Beta0.91 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:GTBP) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GTBP Stock Alerts